KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Free Cash Flow (2016 - 2025)

Edwards Lifesciences has reported Free Cash Flow over the past 17 years, most recently at $353.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $353.5 million for Q4 2025, up 299.38% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 360.5% YoY), and the annual figure for FY2025 was $1.3 billion, up 360.5%.
  • Free Cash Flow for Q4 2025 was $353.5 million at Edwards Lifesciences, down from $516.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for EW hit a ceiling of $516.2 million in Q3 2025 and a floor of -$177.3 million in Q4 2024.
  • Median Free Cash Flow over the past 5 years was $251.3 million (2022), compared with a mean of $232.4 million.
  • Peak annual rise in Free Cash Flow hit 2100.7% in 2024, while the deepest fall reached 467.08% in 2024.
  • Edwards Lifesciences' Free Cash Flow stood at $283.8 million in 2021, then fell by 24.63% to $213.9 million in 2022, then tumbled by 77.42% to $48.3 million in 2023, then crashed by 467.08% to -$177.3 million in 2024, then surged by 299.38% to $353.5 million in 2025.
  • The last three reported values for Free Cash Flow were $353.5 million (Q4 2025), $516.2 million (Q3 2025), and $240.9 million (Q2 2025) per Business Quant data.